Völker LA, Kaufeld J, Balduin G, Merkel L, Kühne L, Eichenauer DA, Osterholt T, Hägele H, Kann M, Grundmann F, Kolbrink B, Schulte K, Gäckler A, Kribben A, Boss K, Potthoff SA, Rump LC, Schmidt T, Mühlfeld AS, Schulmann K, Hermann M, Gaedeke J, Sauerland K, Bramstedt J, Hinkel UP, Miesbach W, Bauer F, Westhoff TH, Bruck H, Buxhofer-Ausch V, Müller TJ, Wendt R, Harth A, Schreiber A, Seelow E, Tölle M, Gohlisch C, Bieringer M, Geuther G, Jabs WJ, Fischereder M, von Bergwelt-Baildon A, Schönermarck U, Knoebl P, Menne J, Brinkkoetter PT; German TTP-Study Group. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura - PubMed (nih.gov). J Thromb Haemost. 2022 Dec 22:S1538-7836(22)07624-3.
Eller K, Knoebl P, Bakkaloglu SA, Menne JJ, Brinkkoetter PT, Grandt L, Thiem U, Coppo P, Scully M, Haller MC. European Renal Best Practice endorsement of guidelines for diagnosis and therapy of thrombotic thrombocytopaenic purpura published by the International Society on Thrombosis and Haemostasis - PubMed (nih.gov). published by the International Society on Thrombosis and Haemostasis. Nephrol Dial Transplant. 2022 Jun 23;37(7):1229-1234.
Kühne L, Kaufeld J, Völker LA, Wendt R, Schönermarck U, Hägele H, Osterholt T, Eichenauer DA, Bieringer M, von Bergwelt-Baildon A, Fischereder M, Buxhofer-Ausch V, Menne J, Brinkkoetter PT, Knöbl P. Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura - PubMed (nih.gov). Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura. J Thromb Haemost. 2022 Apr;20(4):951-960.
Kühne L, Völker LA, Hagmann H, Hägele H, Osterholt T, Eichenauer DA, Thomas A, Breuer J, Grüttner B, Gottschalk I, Kann M, Benzing T, Thevis M, Müller AM, Brinkkoetter PT. First use of the anti-VWF nanobody caplacizumab to treat iTTP in pregnancy - PubMed (nih.gov). Br J Haematol. 2022 Feb;196(3):e30-e33.
Kaufeld J, Brinkkoetter PT, Schreiber A, Jabs WJ, Bieringer M, Bruck H, Menne J, Völker LA. Caplacizumab: frequent local skin reactions - PubMed (nih.gov). Ann Hematol. 2021 Dec;100(12):3051-3052.
Völker LA, Brinkkoetter PT, Knöbl PN, Krstic M, Kaufeld J, Menne J, Buxhofer-Ausch V, Miesbach W. Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab - PubMed (nih.gov). J Thromb Haemost. 2020 Nov;18(11):3061-3066.
Völker LA, Kaufeld J, Miesbach W, Brähler S, Reinhardt M, Kühne L, Mühlfeld A, Schreiber A, Gaedeke J, Tölle M, Jabs WJ, Özcan F, Markau S, Girndt M, Bauer F, Westhoff TH, Felten H, Hausberg M, Brand M, Gerth J, Bieringer M, Bommer M, Zschiedrich S, Schneider J, Elitok S, Gawlik A, Gäckler A, Kribben A, Schwenger V, Schoenermarck U, Roeder M, Radermacher J, Bramstedt J, Morgner A, Herbst R, Harth A, Potthoff SA, von Auer C, Wendt R, Christ H, Brinkkoetter PT, Menne J. ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP - PubMed (nih.gov). Blood Adv. 2020 Jul 14;4(13):3093-3101.
Völker LA, Kaufeld J, Miesbach W, Brähler S, Reinhardt M, Kühne L, Mühlfeld A, Schreiber A, Gaedeke J, Tölle M, Jabs WJ, Özcan F, Markau S, Girndt M, Bauer F, Westhoff TH, Felten H, Hausberg M, Brand M, Gerth J, Bieringer M, Bommer M, Zschiedrich S, Schneider J, Elitok S, Gawlik A, Gäckler A, Kribben A, Schwenger V, Schoenermarck U, Roeder M, Radermacher J, Bramstedt J, Morgner A, Herbst R, Harth A, Potthoff SA, von Auer C, Wendt R, Christ H, Brinkkoetter PT, Menne J. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura - PubMed (nih.gov). Blood Adv. 2020 Jul 14;4(13):3085-3092.
Völker LA, Grundmann F, Brinkkötter PT. [Acquired thrombotic-thrombocytopenic purpura - patient management with the advent of novel therapeutic agents] - PubMed (nih.gov) Dtsch Med Wochenschr. 2019 Nov;144(22):1572-1575. German.